CTOS2017

Exercise May Mitigate Doxorubicin-related Cardiotoxicity

Exercise May Mitigate Doxorubicin-related Cardiotoxicity

Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.

More Than 25% of Patients With Sarcoma Have Anxiety or Depression

More Than 25% of Patients With Sarcoma Have Anxiety or Depression

By

Researchers at the Seattle Cancer Care Alliance used email and web screening to determine patient quality of life and psychological comorbidities after a sarcoma diagnosis.

Vitamin D Supplementation Recommended for Pediatric Patients With Sarcoma

Vitamin D Supplementation Recommended for Pediatric Patients With Sarcoma

By

Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.

Olaratumab Monotherapy Benefits Patients With Soft Tissue Sarcoma Post-chemotherapy

Olaratumab Monotherapy Benefits Patients With Soft Tissue Sarcoma Post-chemotherapy

By

Researchers presented olaratumab monotherapy subgroup results from a phase 2 trial of patients who were previously treated with olaratumab plus doxorubicin or doxorubicin alone.

Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival

Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival

By

Researchers attempted to determine factors associated with DSS after patients with metastatic disease undergo surgical resection.

BLU-285 May Be Effective for Gastrointestinal Stromal Tumor Regardless of Prior Therapy

BLU-285 May Be Effective for Gastrointestinal Stromal Tumor Regardless of Prior Therapy

By

Researchers are evaluating whether BLU-285, which is active regardless of resistance-associated mutations, is safe and effective among patients with an imatinib-resistant GIST.

CDX-011 Does Not Benefit Patients With Osteosarcoma

CDX-011 Does Not Benefit Patients With Osteosarcoma

By

No significant association between GPNBM levels and disease response was found. Due to futility, the researchers did not pursue a second stage of the trial.

Several Factors Predict Recurrence, Survival Among Patients With Pelvic Ewing Sarcoma

Several Factors Predict Recurrence, Survival Among Patients With Pelvic Ewing Sarcoma

By

As the disease's location can make localized treatment difficult, factors that predict for LR and OS may be helpful for treatment decision-making.

Cediranib May Be Effective in Alveolar Soft Part Sarcoma

Cediranib May Be Effective in Alveolar Soft Part Sarcoma

By

In a randomized phase 2 trial, CASPS, researchers enrolled 48 patients with metastatic ASPS that progressed within the preceding 6 months. The primary endpoint was change in tumor size.

Larotrectinib Shows Promise for Patients With <i>NTRK</i>-fusion Sarcoma

Larotrectinib Shows Promise for Patients With NTRK-fusion Sarcoma

By

Researchers enrolled 11 patients with infantile fibrosarcoma or another sarcoma subtype to receive larotrectinib followed by surgery.

Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma

Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma

By

Researchers reported outcomes for patients who underwent a second resection after disease recurrence.

Five-day Preoperative Radiotherapy May Be as Effective as 5-week Course for Sarcoma

Five-day Preoperative Radiotherapy May Be as Effective as 5-week Course for Sarcoma

By

In an ongoing phase 2 study, researchers are evaluating the safety and efficacy of a 5-day hypofractionated radiotherapy course.

Axitinib With Pembrolizumab Promising for Alveolar Soft Part Sarcoma

Axitinib With Pembrolizumab Promising for Alveolar Soft Part Sarcoma

By

For an ongoing phase 2 trial, researchers are recruiting 30 patients with advanced or metastatic sarcoma to receive the drug combination.

Soft Tissue Sarcoma: Nivolumab With Trabectedin Is Safe and Clinically Active

Soft Tissue Sarcoma: Nivolumab With Trabectedin Is Safe and Clinically Active

By

Trabectedin, an alkylating agent, removes tumor growth-promoting M2 macrophages, leading to more effective natural killer T cell activity.

National Cancer Database May Underestimate the Burden of Sarcomas

National Cancer Database May Underestimate the Burden of Sarcomas

By

Institutional policies determine whether cancers are coded by disease type or organ site, which can lead to miscalculations of the global burden of a particular cancer type.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs